Product is intended for victims of chemical nerve agent attack.
GTC Biotherapeutics will continue to conduct process development and clinical manufacturing services for PharmAthene’s Protexia® program. The manufacturing work is planned to conclude in the third quarter.
Protexia is being developed as a pre- and postexposure therapy for victims of a chemical nerve agent attack. It is a recombinant form of human butyrylcholinesterase (rBChE) produced in the milk of transgenic goats.
